Clinical Transfers®: Optimizing Frontline Immunotherapy for High PD-L1 Expressers with NSCLC

Program Overview

The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of regimens targeting the PD-1/PD-L1 axis. In this activity, Roy S. Herbst, MD, PhD and Sarah B. Goldberg, MD, MPH, share the latest data for current and emerging checkpoint inhibitor monotherapies in advanced NSCLC with high PD-L1 expression and provide expert guidance on optimizing frontline treatment selection.

Credit Expired

Target Audience

Oncologists and pulmonologists involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Analyze key safety and efficacy data for current and emerging frontline immunotherapy options in advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression levels ≥50%
  • Assess the potential impact of emerging frontline immunotherapeutic approaches on treatment selection in patients with advanced NSCLC and high PD-L1 expression

Activity Faculty

Herbst - Suit July 2013[2]

Roy S. Herbst, MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology
Chief of Medical Oncology

Associate Cancer Center Director, Translational Research
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT

Head Shot YMS2312_0228_Goldberg (2)

Sarah B. Goldberg, MD, MPH

Associate Professor of Medicine (Medical Oncology)
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources